Shashi Adsul

545 total citations
35 papers, 318 citations indexed

About

Shashi Adsul is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Shashi Adsul has authored 35 papers receiving a total of 318 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Genetics, 26 papers in Epidemiology and 11 papers in Surgery. Recurrent topics in Shashi Adsul's work include Inflammatory Bowel Disease (32 papers), Microscopic Colitis (25 papers) and Biosimilars and Bioanalytical Methods (6 papers). Shashi Adsul is often cited by papers focused on Inflammatory Bowel Disease (32 papers), Microscopic Colitis (25 papers) and Biosimilars and Bioanalytical Methods (6 papers). Shashi Adsul collaborates with scholars based in United States, Switzerland and Canada. Shashi Adsul's co-authors include Laurent Peyrin‐Biroulet, Silvio Danese, Deng‐Chyang Wu, David A. Schwartz, Ida Hilmi, Karen Lasch, Siew C. Ng, Qasim Khan, Aimee Blake and Fatima Bhayat and has published in prestigious journals such as Gastroenterology, The American Journal of Gastroenterology and Alimentary Pharmacology & Therapeutics.

In The Last Decade

Shashi Adsul

30 papers receiving 316 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shashi Adsul United States	10	243	170	120	54	43	35	318
Daniel Quirk United States	11	315 1.3×	229 1.3×	109 0.9×	57 1.1×	19 0.4×	20	390
Anthony Croft Australia	9	245 1.0×	203 1.2×	77 0.6×	81 1.5×	49 1.1×	17	324
Aurada Cholapranee United States	3	238 1.0×	196 1.2×	76 0.6×	70 1.3×	30 0.7×	6	331
Ana Vieira Portugal	9	222 0.9×	154 0.9×	81 0.7×	91 1.7×	15 0.3×	12	301
Alexandra Ruiz‐Cerulla Spain	9	229 0.9×	218 1.3×	140 1.2×	30 0.6×	21 0.5×	16	330
Timothy E. Ritter United States	11	279 1.1×	215 1.3×	110 0.9×	89 1.6×	50 1.2×	38	442
Lars Gustav Lyckander Norway	9	224 0.9×	163 1.0×	118 1.0×	95 1.8×	17 0.4×	19	413
Hilde Vanpoucke Belgium	10	165 0.7×	193 1.1×	85 0.7×	78 1.4×	59 1.4×	13	393
Carmen Stefănescu France	10	410 1.7×	307 1.8×	188 1.6×	73 1.4×	49 1.1×	14	484
Khadija Chaudrey United States	4	248 1.0×	219 1.3×	102 0.8×	70 1.3×	19 0.4×	15	314

Countries citing papers authored by Shashi Adsul

Since Specialization

Citations

This map shows the geographic impact of Shashi Adsul's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shashi Adsul with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shashi Adsul more than expected).

Fields of papers citing papers by Shashi Adsul

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shashi Adsul. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shashi Adsul. The network helps show where Shashi Adsul may publish in the future.

Co-authorship network of co-authors of Shashi Adsul

This figure shows the co-authorship network connecting the top 25 collaborators of Shashi Adsul. A scholar is included among the top collaborators of Shashi Adsul based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shashi Adsul. Shashi Adsul is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Louis, Édouard, Shaji Sebastian, Britta Siegmund, et al.. (2025). Long-Term Safety of Vedolizumab in Patients With Ulcerative Colitis/Crohn’s Disease: A Prospective Observational Study. Clinical Gastroenterology and Hepatology.

Scharl, Michael, Britt Christensen, Brian Bressler, et al.. (2025). Real-World Clinical Effectiveness and Safety of Vedolizumab and Ustekinumab in Biologic-Naive Patients With Crohn’s Disease By Disease Location. Journal of Clinical Gastroenterology.

Jairath, Vipul, Neeraj Narula, Ryan C. Ungaro, Inmaculada Bautista-Castaño, & Shashi Adsul. (2025). Novel outcomes in inflammatory bowel disease. Journal of Crohn s and Colitis. 19(4). 2 indexed citations

Christensen, Britt, Michael Scharl, Brian Bressler, et al.. (2025). Real-World Clinical Effectiveness and Safety of Vedolizumab and Ustekinumab in Biologic-Naïve Patients With Early or Late Crohn’s Disease: Results From the EVOLVE Expansion Study. Crohn s & Colitis 360. 7(3). otaf031–otaf031.

Peyrin‐Biroulet, Laurent, Shashi Adsul, Andrea Stancati, Jamshid Dehmeshki, & Olga Kubassova. (2024). An artificial intelligence‐driven scoring system to measure histological disease activity in ulcerative colitis. United European Gastroenterology Journal. 12(8). 1028–1033. 15 indexed citations

Danese, Silvio, Bruce E. Sands, Brian G. Feagan, et al.. (2024). S1127 A Randomized, Double-Blind, Placebo-Controlled Trial of Vedolizumab With and Without Upadacitinib in Adults With Crohn’s Disease: Design and Rationale for the VICTRIVA Study. The American Journal of Gastroenterology. 119(10S). S800–S800.

Yarur, Andrés, Gerassimos J. Mantzaris, Song Wang, et al.. (2024). Stratified Patient Profiling for Vedolizumab Effectiveness in Crohn’s Disease: Identifying Optimal Subgroups for Enhanced Treatment Response in the EVOLVE Study. Advances in Therapy. 41(6). 2324–2341. 2 indexed citations

Rimola, Jordi, Jean–Frédéric Colombel, Brian Bressler, et al.. (2024). Magnetic Resonance Enterography Assessment of Transmural Healing with Vedolizumab in Moderate to Severe Crohn’s Disease: Feasibility in the VERSIFY Phase 3 Clinical Trial. Clinical and Experimental Gastroenterology. Volume 17. 9–23. 6 indexed citations

Christensen, Britt, et al.. (2023). P636 Real-world clinical effectiveness and safety of vedolizumab and ustekinumab in biologic-naïve patients with Crohn’s disease: Results from the EVOLVE Expansion study. Journal of Crohn s and Colitis. 17(Supplement_1). i768–i769. 2 indexed citations

10.

Ungaro, Ryan C., et al.. (2023). Impact of Concomitant 5-Aminosalicylic Acid Therapy on Vedolizumab Efficacy and Safety in Inflammatory Bowel Disease: Post Hoc Analyses of Clinical Trial Data. Journal of Crohn s and Colitis. 17(12). 1949–1961. 7 indexed citations

11.

Mantzaris, Gerassimos J., Brian Bressler, Shashi Adsul, et al.. (2023). Effectiveness and safety of vedolizumab and infliximab in biologic-naive patients with Crohn’s disease: results from the EVOLVE study. European Journal of Gastroenterology & Hepatology. 36(3). 281–291. 4 indexed citations

12.

Uzzan, Mathieu, Yoram Bouhnik, María T. Abreu, et al.. (2023). Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential Solutions. Journal of Crohn s and Colitis. 17(7). 1066–1078. 26 indexed citations

13.

Schwartz, David A., Laurent Peyrin‐Biroulet, Karen Lasch, Shashi Adsul, & Silvio Danese. (2021). Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn’s Disease: ENTERPRISE Study. Clinical Gastroenterology and Hepatology. 20(5). 1059–1067.e9. 57 indexed citations

14.

Adsul, Shashi, et al.. (2021). A selective and sensitive UPLC–ESI-MS/MS method for quantification of Pegylated Interferon Alfa-2b in human serum using signature peptide-based quantitation. Journal of Chromatography B. 1180. 122883–122883. 1 indexed citations

15.

Ooi, Choon Jin, Ida Hilmi, Hyo Jong Kim, et al.. (2020). Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study. Intestinal Research. 19(1). 71–82. 16 indexed citations

16.

Danese, Silvio, Krisztina Kisfalvi, Wen‐Wen Zhang, et al.. (2020). S0653 Long-Term Treatment With Vedolizumab SC in Ulcerative Colitis: Interim Results From VISIBLE OLE. The American Journal of Gastroenterology. 115(1). S327–S327. 3 indexed citations

17.

Banerjee, Rupa, Sai Wei Chuah, Ida Hilmi, et al.. (2020). Efficacy and safety of vedolizumab in Crohn’s disease in patients from Asian countries in the GEMINI 2 study. Intestinal Research. 19(1). 83–94. 15 indexed citations

18.

Vermeire, Séverine, Milan Lukáš, Fernando Magro, et al.. (2020). Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn’s Disease or Ulcerative Colitis. Journal of Crohn s and Colitis. 14(8). 1066–1073. 11 indexed citations

19.

Latrémouille-Viau, Dominick, Rebecca Burne, Sherry Shi, Shashi Adsul, & Haridarshan Patel. (2019). P379 Comparison of real-world treatment outcomes with infliximab vs. vedolizumab in biologic-naïve patients with inflammatory bowel disease. Journal of Crohn s and Colitis. 13(Supplement_1). S295–S296. 1 indexed citations

20.

Demuth, Dirk, Haridarshan Patel, & Shashi Adsul. (2018). Real World Treatment Persistence With Vedolizumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. The American Journal of Gastroenterology. 113(Supplement). S370–S372. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact